June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Comparison between the only Usher Syndrome patient implanted with ARGUS II® and patients affected with Retinitis Pigmentosa utilizing the same retinal prosthesis system. One year follow up.
Author Affiliations & Notes
  • Sarah Karam Palos
    Ophthalmology, Barraquer Ophthalmological Center, Zaragoza, Zaragoza, Spain
  • Maximiliano Olivera
    Ophthalmology, Barraquer Ophthalmological Center, Zaragoza, Zaragoza, Spain
  • María Iglesias Álvarez
    Ophthalmology, Barraquer Ophthalmological Center, Zaragoza, Zaragoza, Spain
  • Jeroni Nadal Reus
    Ophthalmology, Barraquer Ophthalmological Center, Zaragoza, Zaragoza, Spain
  • Footnotes
    Commercial Relationships   Sarah Karam Palos, None; Maximiliano Olivera, None; María Iglesias Álvarez, None; Jeroni Nadal Reus, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4689. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sarah Karam Palos, Maximiliano Olivera, María Iglesias Álvarez, Jeroni Nadal Reus; Comparison between the only Usher Syndrome patient implanted with ARGUS II® and patients affected with Retinitis Pigmentosa utilizing the same retinal prosthesis system. One year follow up.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4689.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyze the acquired abilities by the only (worldwide known) Usher Syndrome (US) patient who underwent ARGUS II® retinal prosthesis implant after one year follow up compared to the patients affected with Retinitis Pigmentosa (RP) also implanted with the device in our center.

Methods : We analyzed the results of rehabilitation in our three patients implanted with ARGUS II, two women (41 and 50 years old) diagnosed of Retinitis Pigmentosa, who were legally blind for more than 15 years, and a 51-years-old man diagnosed of Usher Syndrome, legally blind for 16 years. We analyzed general health condition, surgical time and perioperative complications, time to first device power on, light/shadow perception, high contrast shape identification, movement identification, high contrast letters, signs and general life achievements (standard questionnaries and methodology for all the patients), together with using time of the device including both rehabilitation-pauted time and free-will usage of the device.

Results : Surgical time improved from 3:15 hours to 2:20 hours. We relate this time variability due to a logical surgeon's learning curve. No perioperative complications were observed and time to first device power on were the same (15 days) for all cases. After two months of ARGUS II® device usage both patients affected with Retinitis Pigmentosa (RP) showed a much faster progression on rehabilitation therapy and achievements. At the third month US patient showed an extraordinary improvement on the general life tasks and became much more independent for daily life compared to RP patients, being even capable to discriminate a broader contrast gamma. After one year follow-up results are persistent.
Because our study is about the only Usher Syndrome patient in the world with a fully functional ARGUS II® device implanted, we are not able to analyze statistical data.

Conclusions : Although Usher Syndrome is not contemplated as an indication for ARGUS II® implant, mainly because of their learning and communicative impairment, the result observed with our patient should be encouraging to considerate US, and probably other similar conditions, also as retinal prosthesis implants suitable receptors.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×